GLP-1-based therapy discontinuation

GLP-1-based therapy discontinuation has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 25, 2026: “Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap”.

Exposure

1 paper studies it3 findingsUpdated

See all 1 papers on GLP-1-based therapy discontinuation

What did studies of GLP-1-based therapy discontinuation find?

3

Studies of GLP-1-based therapy discontinuation measured 3 outcomes: sarcopenic obesity, cardiometabolic benefits and body weight.

Sarcopenic obesity

upin reviews1

1 study
  1. GLP-1-based therapy discontinuation increases sarcopenic obesity.

    “sarcopenic obesity, driven by preferential fat mass recovery relative to lean mass”

    Review

    Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap

    Cureus

More on Sarcopenic obesity

Cardiometabolic benefits

downin reviews1

1 study
  1. GLP-1-based therapy discontinuation decreases cardiometabolic benefits.

    “a decline in cardiometabolic benefits”

    Review

    Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap

    Cureus

Body weight

upin reviews1

1 study
  1. GLP-1-based therapy discontinuation increases body weight (typically observed within one year of withdrawal).

    “discontinuation of GLP-1-based therapy is consistently followed by rapid weight regain”

    Review

    Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap

    Cureus

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months